IPO News | Hemei Pharmaceutical's Hong Kong stock IPO and “full circulation” of domestic unlisted shares were registered by the China Securities Regulatory Commission

The Zhitong Finance App learned that on July 31, the International Cooperation Department of the China Securities Regulatory Commission issued the “Notice Concerning the “Full Circulation” of Ganzhou Hemei Pharmaceutical Co., Ltd.'s Overseas Issued and Listed Shares and Domestic Unlisted Shares. The company intends to issue no more than 63,491,400 overseas listed common shares and list them on the Hong Kong Stock Exchange. The 24 shareholders of the company intend to convert a total of 253,969,480 domestic unlisted shares into overseas listed shares and list them for circulation on the Hong Kong Stock Exchange.

According to the prospectus, Hemei Pharmaceutical was established in 2002 as a biopharmaceutical company dedicated to the discovery and development of self-developed small-molecule drugs for autoimmune diseases and tumors. As of June 1, 2026, the company's pipeline products covered seven small molecule drug candidates (including the two core products Mufemilast and Hemay022). Mufemilast has received NDA approval in China. In the case of Hemay022, the company is conducting a phase III combination therapy clinical trial for advanced ER+/HER2+ breast cancer.

In 2024 and 2025, the company lost approximately 123 million yuan and 130 million yuan respectively during the year.

Attachments